Arvinas to Participate in Upcoming Investor Conferences
ARVN 11.04.2024
About Gravity Analytica
Recent News
- 01.10.2025 - Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
- 12.10.2024 - Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
- 12.10.2024 - Jeet Mukherjee
Recent Filings
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
- Guggenheim Securities Healthcare Innovation Conferenceon Wednesday, November 13.
- Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be availablehereand on the Events and Presentations section of the Company’s website.
- Jefferies London Healthcare Conferenceon Tuesday, November 19.
- Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be availablehereand on the Events and Presentations section of the Company’s website.
About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visitwww.arvinas.comand connect onLinkedInandX.
Contacts
Investors:Jeff Boyle+1 (347) 247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203) 584-0307Kirsten.Owens@arvinas.com
